Chronická myeloidní leukemie - potřebujeme ještě nové inhibitory tyrosinkináz?

Warning

This publication doesn't include Faculty of Arts. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English Chronic myeloid leukemia - do we still need new tyrosine kinase inhibitors?
Authors

ČIČÁTKOVÁ Petra HORŇÁK Tomáš JURČEK Tomáš ŽÁČKOVÁ Daniela

Year of publication 2023
Type Article in Periodical
Magazine / Source Onkologická revue
MU Faculty or unit

Faculty of Medicine

Citation
Web https://onkologickarevue.cz/cs/chronicka-myeloidni-leukemie-potrebujeme-jeste-nove-inhibitory-tyrosinkinaz
Keywords chronic myeloid leukemia; tyrosine kinase inhibitors; asciminib
Description Asciminib is the newest tyrosine kinase inhibitor used for chronic myeloid leukemia patients' therapy. Asciminib binds a myristoyl pocket of the BCR::ABL1, locking BCR::ABL1 into an inactive conformation. A different mechanism of action may be an advantage in the case of TKIs' acting via the ATP-binding domain failure, and a favorable side effect profile is expected. The following case report describes a chronic myeloid leukemia patient benefitting from the use of asciminib not only by means of achieving a deep molecular response but also of a good quality of life.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.